Tandem Investment Advisors Inc. Sells 82,466 Shares of Zoetis Inc. $ZTS

Tandem Investment Advisors Inc. lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 10.4% in the fourth quarter, Holdings Channel.com reports. The fund owned 707,775 shares of the company’s stock after selling 82,466 shares during the period. Zoetis comprises approximately 3.3% of Tandem Investment Advisors Inc.’s portfolio, making the stock its 17th largest holding. Tandem Investment Advisors Inc.’s holdings in Zoetis were worth $89,052,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. RFG Advisory LLC increased its position in Zoetis by 4.9% during the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock valued at $215,000 after purchasing an additional 80 shares during the period. YANKCOM Partnership lifted its position in shares of Zoetis by 3.5% in the 4th quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock worth $302,000 after purchasing an additional 81 shares during the period. Beese Fulmer Investment Management Inc. boosted its stake in shares of Zoetis by 2.4% during the 3rd quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock valued at $537,000 after purchasing an additional 85 shares in the last quarter. Quest 10 Wealth Builders Inc. boosted its stake in shares of Zoetis by 4.7% during the 4th quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock valued at $240,000 after purchasing an additional 86 shares in the last quarter. Finally, Financial Engines Advisors L.L.C. increased its position in shares of Zoetis by 4.4% during the third quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock valued at $299,000 after buying an additional 87 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on ZTS shares. William Blair restated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. JPMorgan Chase & Co. reduced their target price on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. BTIG Research reissued a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research report on Thursday, February 26th. Weiss Ratings lowered Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Finally, Bank of America increased their price objective on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Friday, February 13th. Seven equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $133.92.

Insider Transactions at Zoetis

In other news, Director Paul Bisaro purchased 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the purchase, the director directly owned 27,862 shares in the company, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael B. Mccallister acquired 3,000 shares of Zoetis stock in a transaction on Monday, May 11th. The shares were purchased at an average price of $77.76 per share, with a total value of $233,280.00. Following the completion of the purchase, the director owned 24,524 shares in the company, valued at $1,906,986.24. This represents a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 11,650 shares of company stock valued at $886,384 in the last quarter. 0.22% of the stock is owned by insiders.

Zoetis Price Performance

ZTS stock opened at $81.26 on Tuesday. The firm has a 50 day moving average price of $107.43 and a 200-day moving average price of $118.17. Zoetis Inc. has a 52-week low of $72.38 and a 52-week high of $172.23. The firm has a market capitalization of $34.06 billion, a price-to-earnings ratio of 13.48, a PEG ratio of 1.33 and a beta of 0.87. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The company had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.88 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.6%. Zoetis’s dividend payout ratio (DPR) is presently 35.16%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.